Calamos Advisors LLC Makes New $1.77 Million Investment in Xenon Pharmaceuticals Inc. $XENE

Calamos Advisors LLC purchased a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 30,374 shares of the biopharmaceutical company’s stock, valued at approximately $1,766,000.

A number of other hedge funds have also recently modified their holdings of XENE. Goldman Sachs Group Inc. lifted its stake in shares of Xenon Pharmaceuticals by 7.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 442,732 shares of the biopharmaceutical company’s stock valued at $14,854,000 after purchasing an additional 32,486 shares during the last quarter. Jump Financial LLC acquired a new stake in shares of Xenon Pharmaceuticals during the 2nd quarter worth about $532,000. Sei Investments Co. purchased a new stake in Xenon Pharmaceuticals in the 2nd quarter valued at about $711,000. The Manufacturers Life Insurance Company purchased a new stake in Xenon Pharmaceuticals in the 2nd quarter valued at about $816,000. Finally, Alliancebernstein L.P. lifted its position in Xenon Pharmaceuticals by 14.2% in the second quarter. Alliancebernstein L.P. now owns 1,518,527 shares of the biopharmaceutical company’s stock valued at $47,530,000 after buying an additional 189,141 shares during the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on XENE. Royal Bank Of Canada raised their price target on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Needham & Company LLC lowered their target price on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a report on Friday, May 8th. Wells Fargo & Company reiterated an “overweight” rating and issued a $69.00 price target on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. Finally, JPMorgan Chase & Co. increased their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $77.20.

Xenon Pharmaceuticals Stock Performance

Shares of XENE opened at $67.71 on Thursday. The company has a market capitalization of $6.55 billion, a PE ratio of -14.41 and a beta of 0.61. Xenon Pharmaceuticals Inc. has a fifty-two week low of $30.00 and a fifty-two week high of $72.66. The stock has a fifty day moving average of $56.79 and a two-hundred day moving average of $51.60.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.17). During the same quarter last year, the firm earned ($0.83) earnings per share. As a group, equities research analysts forecast that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current fiscal year.

Insider Activity

In other Xenon Pharmaceuticals news, Director Gary Patou sold 1,322 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the transaction, the director owned 24,896 shares in the company, valued at $1,322,973.44. The trade was a 5.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Gillian Cannon sold 1,190 shares of the business’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the completion of the transaction, the director owned 1,455 shares in the company, valued at approximately $77,318.70. This trade represents a 44.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.91% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical?stage biopharmaceutical company dedicated to discovering and developing novel, small?molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion?channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion?channel biology and structure?based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.